SG11202110922QA - Camptothecin derivatives - Google Patents

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68037—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a camptothecin [CPT] or derivatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biophysics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Mycology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

SG11202110922QA2019-04-262020-04-10Camptothecin derivativesSG11202110922QA (en)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US201962839440P	2019-04-26	2019-04-26
US201962875169P	2019-07-17	2019-07-17
US202062978159P	2020-02-18	2020-02-18
PCT/US2020/027831WO2020219287A1 (en)	2019-04-26	2020-04-10	Camptothecin derivatives

Publications (1)

Publication Number	Publication Date
SG11202110922QAtrue SG11202110922QA (en)	2021-10-28

Family

ID=70465562

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202110922QASG11202110922QA (en)	2019-04-26	2020-04-10	Camptothecin derivatives

Country Status (21)

Country	Link
US (2)	US11229639B2 (en)
EP (2)	EP3958977B1 (en)
JP (2)	JP7561141B2 (en)
KR (1)	KR20220027828A (en)
CN (2)	CN113766954B (en)
AU (1)	AU2020263231A1 (en)
CA (1)	CA3137125A1 (en)
DK (1)	DK3958977T3 (en)
ES (1)	ES2966473T3 (en)
FI (1)	FI3958977T3 (en)
HR (1)	HRP20231619T1 (en)
HU (1)	HUE065484T2 (en)
IL (2)	IL286846B2 (en)
LT (1)	LT3958977T (en)
PL (1)	PL3958977T3 (en)
PT (1)	PT3958977T (en)
RS (1)	RS64961B1 (en)
SG (1)	SG11202110922QA (en)
SI (1)	SI3958977T1 (en)
TW (1)	TW202106691A (en)
WO (1)	WO2020219287A1 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US12227567B2 (en)	2017-07-25	2025-02-18	Truebinding, Inc.	Treating cancer by blocking the interaction of TIM-3 and its ligand
CA3160557A1 (en)*	2020-01-31	2021-08-05	Innate Pharma	Treatment of cancer
EP4110402A1 (en)	2020-02-25	2023-01-04	Mediboston, Inc.	Camptothecin derivatives and conjugates thereof
CN116157151A (en)	2020-05-26	2023-05-23	真和制药有限公司	Methods of treating inflammatory diseases by blocking galectin-3
WO2022140504A1 (en)*	2020-12-23	2022-06-30	Shanghai Ruotuo Biosciences Co., Ltd.	Antibody-drug conjugates, pharmaceutical compositions, and therapeutic applications
KR20230142710A (en)	2021-02-05	2023-10-11	쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드	Camptothecin compounds, their preparation methods and their applications
CN119504997A (en)*	2021-02-09	2025-02-25	苏州宜联生物医药有限公司	Bioactive substance conjugate and preparation method and use thereof
CA3177067A1 (en)*	2021-05-27	2022-12-01	Zymeworks Inc.	Camptothecin analogues, conjugates and methods of use
US11806405B1 (en)	2021-07-19	2023-11-07	Zeno Management, Inc.	Immunoconjugates and methods
EP4389752A4 (en)	2021-08-19	2025-08-20	Hainan Simcere Zaiming Pharmaceutical Co Ltd	Camptothecin derivative, pharmaceutical composition and use thereof
US20240392033A1 (en)*	2021-08-24	2024-11-28	Kunshan Xinyunda Biotech Co., Ltd.	Antibody-drug conjugate conjugated via breakable linker
US20240376120A1 (en)*	2021-09-01	2024-11-14	Shanghai Best-Link Bioscience, Llc	Camptothecin compound, preparation method therefor and use thereof
WO2023131219A1 (en)*	2022-01-06	2023-07-13	Virtuoso Binco, Inc.	Conjugates, compositions and methods of use
CN118434741A (en)*	2022-01-26	2024-08-02	苏州宜联生物医药有限公司	A method for preparing a drug-linker conjugate
EP4496593A1 (en)	2022-03-23	2025-01-29	Synaffix B.V.	Antibody-conjugates for targeting of tumours expressing nectin-4
JP2025510623A (en)	2022-03-23	2025-04-15	シンアフィックスビー．ブイ．	Antibody conjugates for targeting PTK7-expressing tumors - Patent Application 20070123333
KR20250024743A (en)	2022-03-23	2025-02-19	시나픽스 비.브이.	Antibody-conjugate targeting tumors expressing Trop-2
JP2025510678A (en)	2022-03-23	2025-04-15	シンアフィックスビー．ブイ．	Antibody conjugates for targeting tumors expressing carcinoenvironic antigens - Patent Application 20070229633
AU2023239448A1 (en)	2022-03-25	2024-11-07	Zymeworks Bc Inc.	Antibody-drug conjugates targeting folate receptor alpha and methods of use
EP4514350A1 (en)*	2022-04-29	2025-03-05	Shanghai MicuRx Pharmaceutical Co., Ltd.	Ligand-drug conjugate of camptothecin analogs, intermediates, preparation method therefor, pharmaceutical composition and application thereof
EP4523704A1 (en)	2022-05-12	2025-03-19	Hainan Simcere Zaiming Pharmaceutical Co., Ltd.	Camptothecin derivative and ligand-drug conjugate
CN117143178A (en)*	2022-05-30	2023-12-01	苏州宜联生物医药有限公司	Preparation method of drug linker conjugate and its intermediates
EP4285935A1 (en)*	2022-06-03	2023-12-06	Emergence Therapeutics AG	Novel anti-nectin-4 antibody camptothecin derivative conjugates
EP4554625A1 (en)	2022-07-12	2025-05-21	CytomX Therapeutics, Inc.	Epcam immunoconjugates and uses thereof
EP4556026A1 (en)*	2022-07-14	2025-05-21	Medilink Therapeutics (Suzhou) Co., Ltd.	Antibody-drug conjugate, and preparation method therefor and use thereof
EP4309676A1 (en)*	2022-07-22	2024-01-24	Emergence Therapeutics AG	Novel anti-nectin-4 antibody camptothecin derivative conjugates
WO2024020734A1 (en)*	2022-07-25	2024-02-01	Immunogen, Inc.	Novel processes for preparing camptothecin derivatives
CN117510515A (en)*	2022-07-28	2024-02-06	明慧医药（杭州）有限公司	Toxin molecules suitable for antibody-drug conjugates
WO2024050031A2 (en)*	2022-08-31	2024-03-07	Bionecure Therapeutics Inc	Novel camptothecin derivatves as antibody-drug conjugates (adc) payloads
WO2024054089A1 (en)*	2022-09-08	2024-03-14	주식회사 피노바이오	Novel camptothecin derivatives and carrier-drug conjugate comprising same
TWI876557B (en)*	2022-09-30	2025-03-11	臺北醫學大學	Monoclonal antibody used for diagnosis and early onset of prostate cancer
AU2023359114A1 (en)	2022-10-09	2025-04-24	LaNova Medicines Limited	Compounds, compositions and methods
AU2023365995A1 (en)*	2022-10-18	2025-04-03	Zymeworks Bc Inc.	Antibody-drug conjugates targeting glypican-3 and methods of use
WO2024086744A2 (en)*	2022-10-20	2024-04-25	Solve Therapeutics, Inc.	Compositions and uses thereof
EP4623937A1 (en)*	2022-11-25	2025-10-01	Minghui Pharmaceutical (Hangzhou) Limited	Anti-tumor compound and use thereof
CN116712563A (en)*	2022-12-29	2023-09-08	杭州爱科瑞思生物医药有限公司	Antibody conjugated drugs of N-haloalkyl substituted camptothecin derivatives
CN116870187A (en)*	2022-12-29	2023-10-13	杭州爱科瑞思生物医药有限公司	Antibody conjugated drugs of N-oxacycloalkyl-substituted camptothecin derivatives
CN116712561A (en)*	2022-12-29	2023-09-08	杭州爱科瑞思生物医药有限公司	Antibody-drug conjugates containing an N-methyleneamide linker
CN116253741B (en)*	2022-12-30	2024-02-02	上海禧耀医药科技有限公司	Synthesis method of belotekang derivative
US20240293569A1 (en)*	2023-02-10	2024-09-05	Pinotbio, Inc.	Linker for antibody-drug conjugate
CN119630672A (en)*	2023-02-23	2025-03-14	一线医药（杭州）有限公司	Camptothecin derivatives and conjugates thereof, as well as preparation methods and medical uses thereof
WO2024208359A1 (en)*	2023-04-07	2024-10-10	Innovent Biologics (Suzhou) Co., Ltd.	Antibody-drug conjugates of camptothecin derivatives and uses thereof
WO2024255740A1 (en)*	2023-06-13	2024-12-19	成都倍特药业股份有限公司	Camptothecin derivative for treating or preventing cancer, and antibody-drug conjugate thereof
WO2025078841A2 (en)	2023-10-11	2025-04-17	Antikor Biopharma Limited	Antibodies, conjugates, and uses thereof
CN120058721A (en)*	2024-01-08	2025-05-30	杭州爱科瑞思生物医药有限公司	Preparation and application of 7-fluoroalkyl substituted camptothecine derivative
WO2025153001A1 (en)*	2024-01-17	2025-07-24	北京泰德制药股份有限公司	Antibody-drug conjugate containing thiazolo[5,4-b]pyridine structure and use thereof
WO2025184362A1 (en)*	2024-02-28	2025-09-04	Macrogenics Inc.	Adam9 antibody-drug conjugates
CN119101060A (en)*	2024-06-13	2024-12-10	天津中医药大学	Camptothecin derivatives and preparation methods and applications thereof
CN119350434B (en)*	2024-12-24	2025-04-29	苏州共康医药科技有限公司	A process for synthesizing a cleavable linker Ala-Ala-Ala

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
JPH0615547B2 (en)*	1988-01-20	1994-03-02	株式会社ヤクルト本社	Novel camptothecin derivative
US5208020A (en)	1989-10-25	1993-05-04	Immunogen Inc.	Cytotoxic agents comprising maytansinoids and their therapeutic use
US5559235A (en)*	1991-10-29	1996-09-24	Glaxo Wellcome Inc.	Water soluble camptothecin derivatives
ATE136898T1 (en)*	1991-10-29	1996-05-15	Glaxo Wellcome Inc	WATER SOLUBLE CAMPTOTHECINE DERIVATIVES
ES2149768T3 (en)	1992-03-25	2000-11-16	Immunogen Inc	CONJUGATES OF BINDING AGENTS OF CELLS DERIVED FROM CC-1065.
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US20080152586A1 (en)	1992-09-25	2008-06-26	Avipep Pty Limited	High avidity polyvalent and polyspecific reagents
US6355780B1 (en)	1995-02-22	2002-03-12	Yeda Research And Development Co. Ltd.	Antibodies to the death domain motifs of regulatory proteins
DE19640207A1 (en)*	1996-09-30	1998-04-02	Bayer Ag	Glycoconjugates of modified camptothecin derivatives (A or B ring linkage)
US7115396B2 (en)	1998-12-10	2006-10-03	Compound Therapeutics, Inc.	Protein scaffolds for antibody mimics and other binding proteins
ES2276708T3 (en)	1999-11-24	2007-07-01	Immunogen, Inc.	CYTOTOXIC AGENTS UNDERSTANDING TAXANS AND THERAPEUTIC USE.
US6268375B1 (en)*	1999-12-29	2001-07-31	Research Triangle Institute	10, 11-difluoromethylenedioxycamptothecin compounds with topoisomerase I inhibition
ATE448301T1 (en)	2000-09-08	2009-11-15	Univ Zuerich	COLLECTION OF PROTEINS WITH REPEATING SEQUENCES (REPEAT PROTEINS) THAT CONTAIN REPETITIVE SEQUENCE MODULES
US6441163B1 (en)	2001-05-31	2002-08-27	Immunogen, Inc.	Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en)	2001-12-21	2004-04-06	Immunogen Inc.	Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US8877901B2 (en)	2002-12-13	2014-11-04	Immunomedics, Inc.	Camptothecin-binding moiety conjugates
US6756397B2 (en)	2002-04-05	2004-06-29	Immunogen, Inc.	Prodrugs of CC-1065 analogs
WO2004013093A2 (en)	2002-08-02	2004-02-12	Immunogen, Inc.	Cytotoxic agents containing novel potent taxanes and their therapeutic use
WO2004016801A2 (en)	2002-08-16	2004-02-26	Immunogen, Inc.	Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
PT1578446E (en)	2002-11-07	2015-07-22	Immunogen Inc	Anti-cd33 antibodies and method for treatment of acute myeloid leukemia using the same
US8088387B2 (en)	2003-10-10	2012-01-03	Immunogen Inc.	Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en)	2003-05-20	2007-10-02	Immunogen Inc.	Cytotoxic agents comprising new maytansinoids
US7067666B2 (en)	2003-06-27	2006-06-27	Research Triangle Institute	7-substituted camptothecin and camptothecin analogs and methods for producing the same
WO2005082023A2 (en)	2004-02-23	2005-09-09	Genentech, Inc.	Heterocyclic self-immolative linkers and conjugates
EP1853322B1 (en)	2005-02-11	2014-06-25	ImmunoGen, Inc.	Process for preparing maytansinoid antibody conjugates
RU2412249C2 (en)	2005-07-08	2011-02-20	Юниверсити Оф Цюрих	Phage display with application of cotranslational translocation of fused polypeptides
NZ716641A (en)	2005-08-24	2017-06-30	Immunogen Inc	Process for preparing maytansinoid antibody conjugates
CA2620886C (en)	2005-08-31	2017-03-14	The Regents Of The University Of California	Cellular libraries of peptide sequences (clips) and methods of using the same
US8623356B2 (en)	2005-11-29	2014-01-07	The University Of Sydney	Demibodies: dimerization-activated therapeutic agents
WO2007098611A1 (en)	2006-03-03	2007-09-07	Queen's University At Kingston	Compositions for treatment of cancer
SG172656A1 (en)	2006-05-30	2011-07-28	Genentech Inc	Antibodies and immunoconjugates and uses therefor
US8301398B2 (en)	2006-06-22	2012-10-30	Walter And Eliza Hall Institute Of Medical Research	Structure of the insulin receptor ectodomain
US20090304719A1 (en)	2007-08-22	2009-12-10	Patrick Daugherty	Activatable binding polypeptides and methods of identification and use thereof
WO2009040338A1 (en)	2007-09-24	2009-04-02	University Of Zürich	Designed armadillo repeat proteins
RU2503687C2 (en)	2008-04-30	2014-01-10	Иммьюноджен, Инк.	Stitching reagents and their use
KR20100137585A (en)	2008-04-30	2010-12-30	이뮤노젠 아이엔씨	Strong Complexes and Hydrophilic Linkers
KR101098335B1 (en)	2008-07-18	2011-12-26	성균관대학교산학협력단	Cinchona-based bifucntional organocatalysts and method for preparing chiral hemiesters by asymmetric ring opening reaction of meso-cyclic acid anhydrides using the same
MX2011004550A (en)	2008-10-31	2011-07-20	Centocor Ortho Biotech Inc	Fibronectin type iii domain based scaffold compositions, methods and uses.
US20100189651A1 (en)	2009-01-12	2010-07-29	Cytomx Therapeutics, Llc	Modified antibody compositions, methods of making and using thereof
MX2011008566A (en)	2009-02-12	2011-11-29	Janssen Biotech Inc	Fibronectin type iii domain based scaffold compositions, methods and uses.
US9315581B2 (en)	2009-12-23	2016-04-19	A Vipep Pty Limited	Immuno-conjugates and methods for producing them
AR080301A1 (en)	2010-02-24	2012-03-28	Immunogen Inc	ANTIBODIES AND IMMUNOCONJUGADOS OF FOLATO RECEIVER 1 AND ITS USES
DK2544719T3 (en)	2010-03-12	2019-10-14	Debiopharm Int Sa	CD37-BINDING MOLECULES AND IMMUNCONJUGATES THEREOF
RS55163B1 (en)	2010-04-30	2017-01-31	Janssen Biotech Inc	Stabilized fibronectin domain compositions, methods and uses
CN103328505B (en)	2010-10-29	2015-12-02	伊缪诺金公司	Non-antagonistic EGFR binding molecules and immunoconjugates thereof
EP2632490A4 (en)	2010-10-29	2014-10-22	Immunogen Inc	Novel egfr-binding molecules and immunoconjugates thereof
CN113896731A (en)	2011-02-15	2022-01-07	伊缪诺金公司	Cytotoxic benzodiazepine derivatives
WO2012135675A2 (en)	2011-04-01	2012-10-04	Immunogen, Inc.	Methods for increasing efficacy of folr1 cancer therapy
EP2524929A1 (en)	2011-05-17	2012-11-21	Sanofi	Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
WO2014026136A2 (en)	2012-08-10	2014-02-13	Cytomx Therapeutics, Inc.	Protease-resistant systems for polypeptide display and methods of making and using thereof
CN106163556B (en)	2013-09-25	2024-04-09	西托姆克斯治疗公司	Matrix metalloproteinase substrates and other cleavable moieties and methods of use thereof
KR102535900B1 (en)	2013-12-25	2023-05-26	다이이찌 산쿄 가부시키가이샤	Anti-trop2 antibody-drug conjugate
CN106459153B (en)	2014-01-31	2021-12-21	西托姆克斯治疗公司	Substrates and other cleavable moieties for proteolytic enzymes and U-type plasminogen activators and methods of use thereof
MA41374A (en)	2015-01-20	2017-11-28	Cytomx Therapeutics Inc	MATRIX METALLOPROTEASE CLIVABLE AND SERINE PROTEASE CLIVABLE SUBSTRATES AND METHODS OF USE THEREOF
EP3708585A1 (en)	2015-05-04	2020-09-16	CytomX Therapeutics, Inc.	Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereof
WO2018119196A1 (en)	2016-12-23	2018-06-28	Immunogen, Inc.	Immunoconjugates targeting adam9 and methods of use thereof
EP3773736A4 (en)	2018-04-06	2022-01-05	Seagen Inc.	Camptothecin peptide conjugates

2020
- 2020-04-10SGSG11202110922QApatent/SG11202110922QA/enunknown
- 2020-04-10FIFIEP20722197.9Tpatent/FI3958977T3/enactive
- 2020-04-10KRKR1020217038788Apatent/KR20220027828A/enactivePending
- 2020-04-10ILIL286846Apatent/IL286846B2/enunknown
- 2020-04-10EPEP20722197.9Apatent/EP3958977B1/enactiveActive
- 2020-04-10CACA3137125Apatent/CA3137125A1/enactivePending
- 2020-04-10CNCN202080031665.2Apatent/CN113766954B/enactiveActive
- 2020-04-10AUAU2020263231Apatent/AU2020263231A1/enactivePending
- 2020-04-10HRHRP20231619TTpatent/HRP20231619T1/enunknown
- 2020-04-10PTPT207221979Tpatent/PT3958977T/enunknown
- 2020-04-10ESES20722197Tpatent/ES2966473T3/enactiveActive
- 2020-04-10RSRS20231182Apatent/RS64961B1/enunknown
- 2020-04-10LTLTEPPCT/US2020/027831Tpatent/LT3958977T/enunknown
- 2020-04-10SISI202030336Tpatent/SI3958977T1/enunknown
- 2020-04-10JPJP2021563605Apatent/JP7561141B2/enactiveActive
- 2020-04-10WOPCT/US2020/027831patent/WO2020219287A1/ennot_activeCeased
- 2020-04-10HUHUE20722197Apatent/HUE065484T2/enunknown
- 2020-04-10CNCN202411268191.XApatent/CN119119176A/enactivePending
- 2020-04-10ILIL317911Apatent/IL317911A/enunknown
- 2020-04-10TWTW109112170Apatent/TW202106691A/enunknown
- 2020-04-10PLPL20722197.9Tpatent/PL3958977T3/enunknown
- 2020-04-10EPEP23196776.1Apatent/EP4316524A3/enactivePending
- 2020-04-10DKDK20722197.9Tpatent/DK3958977T3/enactive
- 2020-09-25USUS17/032,219patent/US11229639B2/enactiveActive
2021
- 2021-10-15USUS17/502,806patent/US20220133711A1/enactivePending
2024
- 2024-09-20JPJP2024163474Apatent/JP2024178310A/enactivePending

Also Published As

Publication number	Publication date
FI3958977T3 (en)	2023-12-12
IL286846A (en)	2021-10-31
JP7561141B2 (en)	2024-10-03
IL286846B1 (en)	2025-02-01
KR20220027828A (en)	2022-03-08
RS64961B1 (en)	2024-01-31
JP2022529854A (en)	2022-06-24
EP3958977A1 (en)	2022-03-02
EP3958977B1 (en)	2023-09-13
TW202106691A (en)	2021-02-16
US11229639B2 (en)	2022-01-25
HRP20231619T1 (en)	2024-04-26
SI3958977T1 (en)	2024-07-31
PL3958977T3 (en)	2024-03-11
AU2020263231A1 (en)	2021-11-18
HUE065484T2 (en)	2024-05-28
ES2966473T3 (en)	2024-04-22
US20210077482A1 (en)	2021-03-18
US20220133711A1 (en)	2022-05-05
EP4316524A3 (en)	2024-04-24
CN119119176A (en)	2024-12-13
CN113766954A (en)	2021-12-07
LT3958977T (en)	2023-12-27
DK3958977T3 (en)	2023-12-11
CN113766954B (en)	2024-09-24
WO2020219287A1 (en)	2020-10-29
CA3137125A1 (en)	2020-10-29
EP4316524A2 (en)	2024-02-07
PT3958977T (en)	2023-12-15
IL286846B2 (en)	2025-06-01
IL317911A (en)	2025-02-01
JP2024178310A (en)	2024-12-24

Publication	Publication Date	Title
SG11202110922QA (en)	2021-10-28	Camptothecin derivatives
IL278990A (en)	2021-01-31	Camptothecin conjugates
ZA202204675B (en)	2022-12-21	New methylquinazolinone derivatives
IL289197A (en)	2022-02-01	2-hydroxycycloalkane-1-carbamoyl derivatives
IL290815A (en)	2022-04-01	Alpha-d-galactopyranoside derivatives
IL283990A (en)	2021-07-29	Substituted oxopyridine derivatives
PL4077334T3 (en)	2025-06-23	Furoindazole derivatives
IL286434A (en)	2021-10-31	Nicorandil derivatives
HUE070859T2 (en)	2025-07-28	Rapamycin derivatives
SG11202107893XA (en)	2021-08-30	Heterocyclic derivatives
SG11202012594RA (en)	2021-02-25	Spirochromane derivatives
IL288950A (en)	2022-02-01	Pyridin-3-yl derivatives
IL290964A (en)	2022-04-01	2-aminoquinazolinone derivative
SMT202300420T1 (en)	2024-01-10	Sulfonylaminobenzamide derivatives
HUE062256T2 (en)	2023-10-28	Dihydrochromene derivatives
IL304189A (en)	2023-09-01	Pyrazoleamide derivatives
GB201919210D0 (en)	2020-02-05	Dihydro-cyclopenta-isoquinoline derivatives
HK40104845A (en)	2024-08-02	Camptothecin derivatives
ZA202200181B (en)	2025-06-25	2-hydroxycycloalkane-1-carbamoyl derivatives
HK40041699A (en)	2021-08-20	Camptothecin conjugates
GB201806948D0 (en)	2018-06-13	Derivatives

Movatterモバイル変換

SG11202110922QA - Camptothecin derivatives - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (4)

Publications (1)

Family

ID=70465562

Family Applications (1)

Country Status (21)

Families Citing this family (49)

Family Cites Families (58)

Also Published As

Similar Documents